Several immunohistochemistry (IHC) assays have been developed to assess tumor programmed death-ligand 1 (PD-L1) expression levels in patients who are candidates for programmed death-1 (PD-1)/PD-L1 ...
An important question that arises when caring for patients referred for phase I clinical trials is, if one studied the patients’ tumors carefully enough, would there be targets in those patients’ ...
Programmed death 1 ligand 1 (PD-L1) Immunohistochemistry (IHC) is the key FDA-approved predictive marker to identify responders to anti-PD1 axis drugs. Multiple PD-L1 IHC assays with various ...
Impact of insulin-like growth factor 1 receptor (IGF1R) and amphiregulin (AREG) expressions on survival in patients with stage II/III gastric cancer enrolled in the ACTS-GC study. Multivariate ...
The combination of digital pathology with immunohistochemistry is helping to resolve a major issue that has until now limited the accuracy and reliability of the immunohistochemical technique. In a ...
In a recent study published in the journal Frontiers in Immunology, researchers use a multi-omics approach combining immune cell-enriched single-cell transcriptomics (scRNA-seq), microarray analysis, ...
Researchers from Lund University (Sweden) have investigated the tumor immune microenvironment of primary triple-negative breast cancer using digital image analysis of IHC-stained immune cells. To do ...
The field of proteomics has undergone rapid advancements over the last decade and protein microarrays have emerged as a promising technological platform for the challenging task of studying complex ...
Scientific advances in the field of genetics and gene-expression profiling have revolutionized the concept of patient-tailored treatment. Analysis of differential gene-expression patterns across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results